This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HSGX Histogenics (HSGX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Histogenics Stock (NASDAQ:HSGX) 30 days 90 days 365 days Advanced Chart Get Histogenics alerts:Sign Up Key Stats Today's Range$0.93▼$0.9750-Day Range$0.16▼$3.0752-Week Range$0.08▼$1.43Volume3.28 million shsAverage Volume9.06 million shsMarket Capitalization$90.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts. Read More Receive HSGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Histogenics and its competitors with MarketBeat's FREE daily newsletter. Email Address HSGX Stock News HeadlinesTraphaco JSC TRAJuly 31, 2024 | morningstar.comMFeargal Sharkey: Desperate revival of failed policies doesn’t add upApril 7, 2023 | thetimes.co.ukTTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House document might be the real trigger. One market expert who predicted major collapses in 2008 is now warning of a second, far more explosive directive tied to America’s most vital resource. If he’s right, it could set off a financial shock unlike anything we’ve seen in decades.July 6 at 2:00 AM | Porter & Company (Ad)Aspect Biosystems Appoints Three New Board Members - StreetInsider.comSeptember 21, 2022 | streetinsider.comAspect Biosystems Appoints Three New Board Members - Business WireSeptember 21, 2022 | businesswire.comAre Ocugen Or Amarin Good Stocks To Buy? - Investing.comAugust 24, 2022 | investing.com2022-08-05 | NDAQ:OCGN | Press Release | Ocugen, Inc. - StockhouseAugust 5, 2022 | stockhouse.comOcugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - GuruFocus.comJune 23, 2022 | gurufocus.comSee More Headlines HSGX Stock Analysis - Frequently Asked Questions How were Histogenics' earnings last quarter? Histogenics Corp (NASDAQ:HSGX) released its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.10. When did Histogenics IPO? Histogenics (HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Histogenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Histogenics investors own include Interpace Biosciences (IDXG), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), Novavax (NVAX), SCYNEXIS (SCYX), Ocular Therapeutix (OCUL) and OPKO Health (OPK). Company Calendar Last Earnings8/09/2018Today7/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical Appliances & Supplies Sub-IndustryN/A Current SymbolNASDAQ:HSGX CIK1372299 Webwww.histogenics.com Phone781-547-7900FaxN/AEmployees49Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.96% Return on Assets18.40% Debt Debt-to-Equity RatioN/A Current Ratio4.05 Quick Ratio4.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-95.70Miscellaneous Outstanding Shares94,599,000Free FloatN/AMarket Cap$90.53 million OptionableNot Optionable Beta3.10 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:HSGX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s BIGGEST setup yet.After another undefeated quarter, “Market Wizard” Larry Benedict is sounding the alarm on a $194 trillion mark...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogenics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Histogenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
